Six-year follow-up of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM and ENDORSE

被引：0
|
作者：
Arnold, D. L. [1 ,2 ]
Fox, R. J. [3 ]
Gold, R. [4 ]
Havrdova, E. [5 ]
Kappos, L. [6 ]
Yousry, T. [7 ]
MacManus, D. [7 ]
Zhang, R. [8 ]
Yang, M. [8 ]
Rana, J. [8 ]
机构：
[1] McGill Univ, NeuroRx Res, Montreal, PQ, Canada
[2] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
[3] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[4] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[5] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague, Czech Republic
[6] Univ Basel Hosp, Basel Neurol, CH-4031 Basel, Switzerland
[7] UCL, Inst Neurol, Queen Sq Multiple Sclerosis Ctr, NMR Res Unit, London, England
[8] Biogen Inc, Cambridge, MA 02142 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P566
引用
收藏
页码：264 / 265
页数：2
相关论文
共 50 条
  • [31] Five-year follow-up of delayed-release dimethyl fumarate in RRMS: integrated clinical efficacy data from the DEFINE, CONFIRM, and ENDORSE Studies
    Hutchinson, M.
    Gold, R.
    Fox, R. J.
    Phillips, J. T.
    Bar-Or, A.
    Kappos, L.
    Sheikh, S.
    Zhang, R.
    Yang, M.
    Kurukulasuriya, N. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 153 - 153
  • [32] Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS)
    Gold, Ralf
    Giovannoni, Gavin
    Phillips, J. Theodore
    Fox, Robert J.
    Zhang, Annie
    Meltzer, Leslie
    Kurukulasuriya, Nuwan C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (01) : 57 - 66
  • [33] An interim analysis of quality of life in patients with relapsing-remitting multiple sclerosis treated with delayed-release dimethyl fumarate
    Sarda, S. P.
    Kita, M.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Phillips, T.
    Okwuokenye, M.
    Kong, J.
    Zhang, R.
    Kurukulasuriya, N. C.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 413 - 414
  • [34] Three-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated magnetic resonance imaging (MRI) outcomes from DEFINE, CONFIRM, and ENDORSE
    Miller, D. H.
    Fox, R. J.
    Gold, R.
    Havrdova, E.
    Kappos, L.
    MacManus, D.
    Yousry, T.
    Zhang, R.
    Yang, M.
    Viglietta, V.
    Sheikh, S. I.
    Dawson, K. T.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 461 - 462
  • [35] Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis using a composite measure of disability: integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Bar-Or, A.
    Gold, R.
    Fox, R. J.
    Phillips, J. T.
    Giovannoni, G.
    Kappos, L.
    Havrdova, E.
    Hutchinson, M.
    Potts, J.
    Marantz, J. L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 303 - 304
  • [36] The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
    Su, Wenqing
    Kansal, Anuraag
    Vicente, Colin
    Deniz, Baris
    Sarda, Sujata
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 718 - 727
  • [37] Safety profile of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: long-term interim results from the ENDORSE extension study
    Pozzilli, C.
    Phillips, J. T.
    Fox, R. J.
    Selmaj, K.
    Zhang, R.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Gold, R.
    JOURNAL OF NEUROLOGY, 2014, 261 : S439 - S439
  • [38] Safety profile of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: long-term interim results from the ENDORSE extension study
    Pozzilli, C.
    Phillips, J. T.
    Fox, R. J.
    Selmaj, K.
    Zhang, R.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Gold, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 678 - 678
  • [39] Rate of Brain Volume Loss with Long-Term Delayed-Release Dimethyl Fumarate Treatment in Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Results from ENDORSE
    Kappos, Ludwig
    Yousry, Tarek
    Fox, Robert
    Gold, Ralf
    Arnold, Douglas
    Potts, James
    Marantz, Jing
    NEUROLOGY, 2016, 86
  • [40] Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies
    Gold R.
    Giovannoni G.
    Phillips J.T.
    Fox R.J.
    Zhang A.
    Marantz J.L.
    Neurology and Therapy, 2016, 5 (1) : 45 - 57
12345